Published in N Engl J Med on August 31, 2006
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer | NCT02343614
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut (2011) 2.75
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med (2011) 2.64
The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology (2008) 2.56
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2009) 2.55
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation (2014) 2.11
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
TGF-alpha expression as a potential biomarker of risk within the normal-appearing colorectal mucosa of patients with and without incident sporadic adenoma. Cancer Epidemiol Biomarkers Prev (2009) 1.98
Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) (2009) 1.86
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
Spectroscopic microvascular blood detection from the endoscopically normal colonic mucosa: biomarker for neoplasia risk. Gastroenterology (2008) 1.73
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
Role of Toll-like receptors in gastrointestinal malignancies. Oncogene (2008) 1.69
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A (2009) 1.65
Assessment of the quality of colonoscopy reports: results from a multicenter consortium. Gastrointest Endosc (2009) 1.64
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) (2011) 1.62
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2008) 1.57
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila) (2011) 1.57
Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One (2008) 1.55
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer (2010) 1.51
Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res (2008) 1.48
Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med (2006) 1.45
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int (2011) 1.43
Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol (2011) 1.41
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica (Cairo) (2012) 1.37
Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy (2010) 1.37
Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology. Cancer Prev Res (Phila) (2009) 1.32
Dual roles for immunity in gastrointestinal cancers. J Clin Oncol (2010) 1.31
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst (2014) 1.28
GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res (2010) 1.28
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) (2011) 1.20
Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) (2010) 1.20
Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer (2009) 1.19
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol (2008) 1.18
The role of microRNAs in gastrointestinal cancers. J Gastroenterol (2009) 1.17
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) (2010) 1.15
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology (2012) 1.15
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest (2009) 1.14
Role of LKB1 in lung cancer development. Br J Cancer (2008) 1.14
Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol (2010) 1.14
Cancer prevention research - then and now. Nat Rev Cancer (2009) 1.12
Tumor-host interactions: the role of inflammation. Histochem Cell Biol (2008) 1.11
Notes from the field: "green" chemoprevention as frugal medicine. Cancer Prev Res (Phila) (2012) 1.11
Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther (2012) 1.10
TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10
HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol (2011) 1.10
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer (2008) 1.09
Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev (2014) 1.07
Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol (2014) 1.07
Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res (2011) 1.06
Tumor stroma as targets for cancer therapy. Pharmacol Ther (2012) 1.06
The use of animal models for cancer chemoprevention drug development. Semin Oncol (2010) 1.05
Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis (2008) 1.05
A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J (2008) 1.04
The Role of Inflammation in the Pathogenesis of Colorectal Cancer. Curr Colorectal Cancer Rep (2009) 1.04
Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol (2007) 1.03
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02
EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. Am J Respir Cell Mol Biol (2007) 1.02
Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis. J Clin Invest (2014) 1.02
Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int J Cancer (2009) 1.01
Prevention of colorectal cancer: diet, chemoprevention, and lifestyle. Gastroenterol Clin North Am (2008) 1.00
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) (2011) 1.00
Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors. Arch Drug Inf (2009) 0.99
Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Am J Transl Res (2010) 0.98
Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer (2008) 0.98
Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci U S A (2012) 0.98
Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res (Phila) (2009) 0.98
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. Cancer Prev Res (Phila) (2010) 0.98
Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer (2010) 0.98
Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription. J Biol Chem (2008) 0.97
Colorectal cancer prevention through dietary and lifestyle modifications. Cancer Microenviron (2011) 0.97
Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev Res (Phila) (2009) 0.97
Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions. Semin Oncol (2011) 0.97
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology (2009) 0.97
NSAIDs and colorectal cancer prevention. J Gastroenterol (2009) 0.96
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr (2010) 13.12
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med (2011) 8.54
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Prior image constrained compressed sensing (PICCS): a method to accurately reconstruct dynamic CT images from highly undersampled projection data sets. Med Phys (2008) 7.52
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 6.54
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol (2009) 5.05
CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (2009) 5.00
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med (2005) 4.27
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst (2005) 4.14
The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding. Gastrointest Endosc (2013) 4.07
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 3.36
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (2004) 3.31
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe (2013) 3.21
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin (2006) 3.21
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc (2008) 3.13
Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med (2013) 3.09
Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst (2010) 3.05
Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol (2005) 3.01
Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol (2004) 2.98
Computer-assisted personalized sedation for upper endoscopy and colonoscopy: a comparative, multicenter randomized study. Gastrointest Endosc (2010) 2.96
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol (2009) 2.94
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther (2006) 2.85
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol (2008) 2.80
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine (2007) 2.76
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst (2008) 2.72
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
What information should a sponsor of a randomized trial receive during its conduct? Clin Trials (2011) 2.69
An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res (2009) 2.69
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst (2004) 2.68
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 2.65
Endoscopic, deep mural implantation of Enteryx for the treatment of GERD: 6-month follow-up of a multicenter trial. Am J Gastroenterol (2003) 2.63
The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59
Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst (2009) 2.56
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology (2008) 2.56
Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53
Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc (2014) 2.52
Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut (2013) 2.50
The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc (2014) 2.47